STUB1 and ovarian cancer: To identify novel prognostic markers that can be detected with non-invasive techniques (such as liquid biopsies) in ovarian cancer patients, we sought to identify candidate CHIP variants whose frequencies were higher in pre-NACT samples from NACT-PR patients than those from NACT-ER patients (Figure 3C).